Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by China Medical University Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
National Taiwan University Hospital
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01249079
First received: November 24, 2010
Last updated: November 30, 2010
Last verified: October 2010
  Purpose

This proposal responds to Request for Applications RFA-MH-08-131, which seeks applications that propose to enrich pre-existing resources for schizophrenia in the National Institute of Mental Health (NIMH) Human Genetics Initiative and to apply genomic methods to further the investigators understanding of the molecular etiology of the disorder. The overarching aims of this proposal are to quickly and cost-effectively ascertain a large sample of trio families affected by schizophrenia, and to discover causal variants for the disorder in the first family-based genome-wide association study (GWAS) of the disorder. In Taiwan, there is no such kind of policy to support this kind of GWAS study as it is a very expensive study, including collecting large family samples and genome-wide single-nucleotide polymorphism (SNP) scanning. The investigators, thus, collaborate with Professor Ming T, Tsuang and his entended subcontracted researchers to apply for this project. The investigators, the research team in Taiwan, will collect 3800 trio families (11400 subjects) of schizophrenia. Through additional ascertainment within this framework, the investigators will collect an aggregate sample with adequate power for detecting in a GWAS those variants that make even small contributions to the risk for the disorder.

The investigators will meet the overarching goals of this project by accomplishing several Specific Aims, as follows: 1) Rapidly ascertain schizophrenia trio families from Taiwanese clinical ascertainment sites; 2) Supplement NIMH Genetics Initiative collections by sending all clinical data and biomaterials to the appropriate repositories; 3) Assess the association of schizophrenia with a genome-wide panel of single-nucleotide polymorphisms (SNPs) and their constituent haplotypes; 4) Analyze quantitative schizophrenia phenotypes such as age at onset ; 5) Perform a genome-wide survey for copy-number variations related to schizophrenia; 6) Test for gene-gene interactions (epistasis); and 7) Test for gene-environment interactions, such as the well-established effect of season of birth.


Condition Intervention
Schizophrenia
Other: No intervention would be provided in this research

Study Type: Observational
Study Design: Observational Model: Family-Based
Official Title: Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

Estimated Enrollment: 600
Study Start Date: October 2010
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Schizophrenia Family Other: No intervention would be provided in this research
No intervention would be provided in this research,but need to draw blood

  Eligibility

Ages Eligible for Study:   16 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Schizophrenia patients and their biological parents

Criteria

Inclusion Criteria:

  • clinical diagnosis of schizophrenia and their parents, and parents are still alive

Exclusion Criteria:

  • person with Mental Retardation
  • persons with epilepsy
  • alcohol or substance abuse combined
  • in combination with other organic brain damage syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01249079

Contacts
Contact: Hai-Gwo Hwu 886-2-23122453 ext 66785 haigohwu@ntu.edu.tw

Locations
Taiwan
China Medical University Hospital Recruiting
Taichung, Taiwan
Contact: Hsien-Yuan Lane         
Sponsors and Collaborators
China Medical University Hospital
National Taiwan University Hospital
Investigators
Study Director: Hsien-Yuan Lane China Medical University Hospital
  More Information

No publications provided

Responsible Party: Hsien-Yuan Lane,Chief of Psychiatry Department, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01249079     History of Changes
Other Study ID Numbers: DMR99-IRB-214
Study First Received: November 24, 2010
Last Updated: November 30, 2010
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders

ClinicalTrials.gov processed this record on September 22, 2014